Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBritish American Tobacco Regulatory News (BATS)

Share Price Information for British American Tobacco (BATS)

Share Price is delayed by 15 minutes
Get Live Data
4,404.00    84.00 (1.94%)
Bid:
4,423.00
Ask:
4,425.00
Spread: 2.00 (0.045%)
Market Cap: £95.19b
BATS Live PriceLast checked at - London Stock Exchange

Intraday British American Tobacco Share Chart

Share Buyback Programme

10 Dec 2025 07:00

RNS Number : 8904K
British American Tobacco PLC
10 December 2025
 

British American Tobacco p.l.c. (the "Company")

 

10 December 2025

 

Extension of Share Buyback Programme

 

Further to its announcement on 9 December 2025 in its trading update, the Company announces the extension of its share buyback programme, originally announced on 18 March 2024, by up to £1.3 billion for 2026 ("the Programme").

 

The Company has entered into an irrevocable, non-discretionary agreement with UBS AG London Branch ("UBS") to purchase ordinary shares of the Company ("Shares") for the next tranche of the Programme, which is expected to be completed during the Company's closed period commencing on 2 January 2026 and ending at the close of business on 11 February 2026, the day prior to the release of its full year preliminary results. 

 

UBS will make its trading decisions in relation to the Company's Shares independently of, and uninfluenced by, the Company.

The purpose of the Programme is to reduce the share capital of the Company. The Shares repurchased will be cancelled. The maximum number of Shares permitted to be purchased by the Company under the Programme, pursuant to the authority granted by its shareholders at the Company's 2025 AGM, is 220,451,469 Shares (less the number of Shares subsequently purchased by the Company under the Programme since that authority was granted).

Any purchases of Shares by the Company in relation to this announcement will be undertaken within certain pre-set parameters, and in accordance with both the Company's general authority to repurchase shares granted by its shareholders at the Company's 2025 AGM (the "Authority"), the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (2016/1052), in each case as such legislation forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended), and Chapter 9.6 of the Financial Conduct Authority's UK Listing Rules.

Pursuant to the Authority, the maximum price which may be paid for a Share is an amount (exclusive of taxes and expenses) equal to the higher of:

- 105 per cent of the average market value of a Share as derived from the LSE's Daily Official List for the five business days immediately preceding the day on which the Share is purchased, in accordance with Listing Rule 9.6.1 of the Listing Rules published pursuant to Part 6 of the Financial Services and Markets Act 2000 ("FSMA") (the "Listing Rules"); and

- the higher of (i) the price of the last independent trade and (ii) the highest current independent purchase bid on the trading venue where the purchase is carried out, including when the shares are traded on different trading venues, in accordance with Article 3(2) of the UK Safe Harbour Regulation.

Enquiries:

 

Investor Relations 

Victoria Buxton: | IR_team@bat.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFSIFMUEISEFE
Date   Source Headline
15th May 20237:00 amRNSBAT announces Tadeu Marroco as Chief Executive
12th May 20234:45 pmRNSDirector/PDMR Shareholding
12th May 202312:10 pmRNSHolding(s) in Company
11th May 20233:25 pmRNSDirector/PDMR Shareholding
9th May 20234:00 pmRNSDirector/PDMR Shareholding
5th May 20232:55 pmRNSDirector/PDMR Shareholding
5th May 20232:50 pmRNSDirector/PDMR Shareholding
5th May 20232:45 pmRNSDirector/PDMR Shareholding
4th May 20233:35 pmRNSDirector/PDMR Shareholding
4th May 20231:10 pmRNSDirector/PDMR Shareholding
2nd May 20239:50 amRNSTotal Voting Rights
25th Apr 20234:05 pmRNSAgreement with the US Department of Justice
24th Apr 20237:15 amRNSDirector Declaration
19th Apr 20235:45 pmRNSResult of AGM
19th Apr 202311:45 amRNSAGM Statement
6th Apr 20231:20 pmRNSDirector/PDMR Shareholding
5th Apr 20234:15 pmRNSDirector/PDMR Shareholding
3rd Apr 20234:39 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:05 amRNSTotal Voting Rights
31st Mar 20234:55 pmRNSDirector/PDMR Shareholding
31st Mar 20234:50 pmRNSDirector/PDMR Shareholding
31st Mar 20234:45 pmRNSDirector/PDMR Shareholding
23rd Mar 20232:50 pmRNSDirector/PDMR Shareholding
23rd Mar 20232:45 pmRNSDirector/PDMR Shareholding
23rd Mar 20232:40 pmRNSDirector/PDMR Shareholding
14th Mar 20234:47 pmRNSPublication of a Prospectus
14th Mar 20238:00 amRNSNotice of AGM
13th Mar 20233:10 pmRNSDirector/PDMR Shareholding
13th Mar 20237:00 amRNSBranch Register: Dividend Finalisation Information
9th Mar 202310:35 amRNSDirector/PDMR Shareholding
8th Mar 202311:10 amRNSDirector/PDMR Shareholding
3rd Mar 20234:40 pmRNSDirector/PDMR Shareholding
3rd Mar 202310:15 amRNSDirector Declaration
2nd Mar 20234:55 pmRNSAnnual Financial Report
1st Mar 202310:00 amRNSTotal Voting Rights
23rd Feb 202311:15 amRNSDirector/PDMR Shareholding
15th Feb 20236:05 pmRNSDirector Declaration
15th Feb 202310:30 amRNSDirector/PDMR Shareholding
14th Feb 20236:15 pmRNSPublication of Final Terms
13th Feb 202310:00 amRNSDirector/PDMR Shareholding
9th Feb 20234:10 pmRNSPublication of Supplementary Prospectus
9th Feb 20237:03 amRNSFinal Results
6th Feb 202312:35 pmRNSDirector/PDMR Shareholding
6th Feb 202312:30 pmRNSDirector/PDMR Shareholding
6th Feb 202312:25 pmRNSDirector/PDMR Shareholding
6th Feb 202312:20 pmRNSDirector/PDMR Shareholding
6th Feb 202312:15 pmRNSDirector/PDMR Shareholding
3rd Feb 202310:30 amRNSDirector/PDMR Shareholding
1st Feb 202312:00 pmRNSTotal Voting Rights
31st Jan 20237:00 amRNSManagement Board Changes & New Regional Structure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.